Insider Selling: CRISPR Therapeutics (NASDAQ:CRSP) General Counsel Sells 2,800 Shares of Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel James Kasinger sold 2,800 shares of CRISPR Therapeutics stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $52.80, for a total transaction of $147,840.00. Following the sale, the general counsel directly owned 87,815 shares of the company’s stock, valued at $4,636,632. This represents a 3.09% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

CRISPR Therapeutics Price Performance

CRSP traded down $1.06 during trading on Thursday, reaching $48.87. The company had a trading volume of 3,284,940 shares, compared to its average volume of 1,997,127. The business’s fifty day moving average price is $54.27 and its 200 day moving average price is $57.34. CRISPR Therapeutics AG has a 12 month low of $30.04 and a 12 month high of $78.48. The company has a market cap of $4.69 billion, a P/E ratio of -7.50 and a beta of 1.72.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Thursday, February 12th. The company reported ($1.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). The company had revenue of $0.86 million during the quarter, compared to the consensus estimate of $4.72 million. CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The firm’s revenue for the quarter was down 97.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.01) earnings per share. As a group, sell-side analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Key Stories Impacting CRISPR Therapeutics

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: FY2025 commercial progress — CRSP reported growth in commercial revenue driven by CASGEVY (reported $116M for FY25, $54M in Q4), which supports the long‑term commercial thesis for the company’s lead product. CRSP FY25 revenue
• Positive Sentiment: Institutional interest — reports show notable additions by some funds (including ARK Invest) in recent quarters, a sign that selective investors see upside at current levels. This can provide a backstop for shares over time. ARK buys
• Neutral Sentiment: Analyst model tweaks — Brookline Capital made small downward tweaks to FY2028–FY2030 EPS forecasts (minor reductions in multi‑year projections). These adjustments are modest and reflect model updates rather than new negative clinical data. (Source: Brookline reports)
• Neutral Sentiment: Short‑interest data appears anomalous — filings in mid‑March show zero reported short interest in the dataset provided, a likely reporting artifact; days‑to‑cover is effectively 0.0 in those numbers, so this item offers no clear directional signal. (Data summary)
• Negative Sentiment: Upsized $550M convertible senior notes offering — CRSP priced $550M of convertible notes due 2031 (upsized from $350M) with an initial conversion price ~ $76.56 (≈45% premium to pre‑deal price). While proceeds (~$536M net) bolster liquidity, the deal introduces potential future dilution if conversions occur and the upsizing/offer timing likely pressured the share price today. Convertible notes PR
• Negative Sentiment: Near‑term market reaction — news flow around the financing and profit taking led to a sharp intraday decline in recent sessions, reinforcing that the convertible deal + analyst updates are the primary drivers of today’s weakness. Market dip

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Mcguire Capital Advisors Inc. acquired a new stake in shares of CRISPR Therapeutics in the fourth quarter worth $25,000. Ramirez Asset Management Inc. acquired a new position in shares of CRISPR Therapeutics in the 4th quarter valued at $26,000. Rothschild Investment LLC boosted its position in shares of CRISPR Therapeutics by 836.7% during the fourth quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock worth $29,000 after buying an additional 502 shares during the period. Thurston Springer Miller Herd & Titak Inc. grew its stake in CRISPR Therapeutics by 196.9% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock worth $30,000 after purchasing an additional 382 shares in the last quarter. Finally, Atlantic Union Bankshares Corp purchased a new stake in CRISPR Therapeutics during the 2nd quarter worth about $33,000. Institutional investors own 69.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. TD Cowen boosted their target price on shares of CRISPR Therapeutics from $40.00 to $45.00 and gave the company a “hold” rating in a report on Friday, February 13th. Evercore reiterated an “outperform” rating and set a $74.00 price target on shares of CRISPR Therapeutics in a report on Friday, February 13th. Bank of America dropped their price target on CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating on the stock in a research report on Thursday, January 22nd. Citizens Jmp reduced their target price on CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating for the company in a report on Friday, January 30th. Finally, Chardan Capital increased their price target on shares of CRISPR Therapeutics from $74.00 to $76.00 and gave the stock a “buy” rating in a report on Saturday, February 14th. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $64.24.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.